Primary gastrointestinal angiosarcoma is an extremely rare disease. We present a unique case in which endoscopic examination of the deep small bowel was necessary to make the diagnosis using spiral enteroscopy.

An 82-year-old man with a history of radiation therapy for prostate cancer was referred for persistent, obscure-overt gastrointestinal bleeding. Recent upper endoscopy with push enteroscopy approximately 20 cm beyond the ligament of Treitz (LOT) was negative. Ileocolonoscopy only revealed blood in the terminal ileum. Computed tomography (CT) angiogram and bleeding scan were negative. The patient received a total of 29 units of packed red blood cells, 10 units of fresh frozen plasma, and 7 units of platelets in the month prior to presentation. On admission to our hospital, his hemoglobin level was 8 g/dL with a normal platelet count and prothrombin time. Anterograde (per os) spiral overtube-assisted enteroscopy was performed. The enteroscope was inserted approximately 230 cm beyond the LOT. Beginning at 40 cm past the LOT, there were innumerable exophytic, polypoid masses that were oozing blood ranging in size from 5 mm to 30 mm (Fig. 1).

The lesions blanketed the entire jejunum. Multiple biopsies were obtained (Video 1). Histopathological examination revealed sheets of epithelioid cells with ample eosinophilic cytoplasm containing pleomorphic nuclei (Fig. 2, 3). Frequent mitoses and primitive vascular channels were identified. The diagnosis of angiosarcoma was confirmed by special stains for vimentin, CD31/34 and factor VIII-related antigen (Fig. 4). The patient died 6 weeks later from intractable bleeding and exsanguination.

Primary jejunal angiosarcoma: an extremely rare tumor diagnosed by means of anterograde spiral enteroscopy

Fig. 1 Endoscopic view of jejunum showing semi-circumferential exophytic bleeding mass.

Fig. 2 Low power magnification (× 100) of small-intestinal lesion showing a normal small-intestinal gland (solid black arrow) and an abnormal vasoformative channel lined with neoplastic epithelioid cells (block arrow).

Fig. 3 High power magnification (× 400) showing an abnormal vasoformative area (solid black arrow) and a plump epithelioid cell with abundant eosinophilic cytoplasm (block arrow).

Fig. 4 Positive factor VIII stain.
Angiosarcoma is a rare, highly aggressive vascular neoplasm primarily involving the skin and soft tissues [1]. Infrequently, angiosarcoma may involve the abdominal organs such as the liver, spleen and adrenals. Primary gastrointestinal angiosarcoma, however, is an extremely rare tumor with only 30 cases described in the literature since 1970 [2]. The exact pathogenesis of angiosarcoma remains unclear, but some predisposing factors include previous radiation therapy, exposure to vinyl chloride, Thorotrast or arsenic, and hemodialysis or chronic lymphedema [3–5]. In most cases of gastrointestinal angiosarcoma, the symptoms are nonspecific and include abdominal pain, weight loss, and anorexia. Overt bleeding with melena or hematochezia is less common, and thus tagging red blood cell scintigraphy (bleeding scan) and often angiogram are not useful. Direct visualization and biopsy of suspected intestinal lesions with either push enteroscopy or overtube-assisted deep enteroscopy is the most reliable method of diagnosis. Histopathological examination of gastrointestinal angiosarcoma usually reveals solid areas of epithelioid cells with abundant eosinophilic cytoplasm. In addition, there are vasoformative areas with anastomosing vessels lined by spindle-shaped cells. Immunohistochemical staining with vimentin, CD31/34 and factor VIII-related antigen confirms the vascular nature of this lesion. Stains for cytokeratin (adenocarcinoma), S100 (neuroma or melanoma), c-kit (gastrointestinal stromal tumor) are negative.

Death from gastrointestinal angiosarcoma is often due to exsanguination. Surgical resection offers the best chance for cure if the disease is limited. Currently there are no well-defined chemotherapy regimens for primary gastrointestinal angiosarcoma, as few randomized clinical trials have been performed. Taxol and thalidomide can be considered because of their antiangiogenic properties [6]. Ifosfamide, docetaxel, and recombinant human interleukin-2 have been reported to be successful [7,8].

Endoscopy_UCTN_Code_CCL_1AC_2AC

Competing interests: None

V. Jayaraman1, M. N. Wilkinson1, S. Nagula1, M. Siebel2, J. C. Bucobo3, S. Zee3, J. M. Buscaglia1

1 Divisions of Gastroenterology, Stony Brook University Medical Center, Stony Brook, New York, USA
2 Divisions of Oncology, Stony Brook University Medical Center, Stony Brook, New York, USA
3 Department of Pathology, Stony Brook University Medical Center, Stony Brook, New York, USA

References

Bibliography
Endoscopy 2011; 43: E219 – E220
© Georg Thieme Verlag KG Stuttgart · New York · ISSN 0013-726X

Corresponding author
V. Jayaraman
Division of Gastroenterology
Stony Brook University Medical Center
100 Nicolls Road
HSC Level 17
Room 060
Stony Brook
NY 11794
Fax: +631-444-8886
vijay.jayaraman@stonybrook.edu